WOBURN, MA – (Business Wire) – Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered a multi-target research, option and license agreement with Moderna, Inc....
Press Release
Leveragen and 92Bio Forge Strategic Alliance to Advance Therapeutics Using Novel Single Domain Antibody Platform
WOBURN, Mass.--Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered into a multi-target commercial license agreement with 92Bio, Inc., a biotech firm focused...